Accessibility Menu
TriSalus Life Sciences logo

TriSalus Life Sciences

(NASDAQ) TLSI

Current Price$4.30
Market Cap$263.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-59%
5 YearN/A
1 Year-9%
1 Month+10%
TriSalus Life Sciences last closing stock price
MetricPriceDate
Last closeUSD 4.292026-07-17
TriSalus Life Sciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.62%USD 4.142026-07-10
1 month+10.28%USD 3.892026-06-17
3 month-7.74%USD 4.652026-04-17
Year to date-38.54%USD 6.982025-12-31
1 year-9.11%USD 4.722025-07-17
Since inception-59.22%USD 10.522021-02-08

TriSalus Life Sciences Financials at a Glance

Market Cap

$263.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$44.88M

Net Income (TTM)

-$27.31M

EPS (TTM)

-$1.41

P/E Ratio

-3.04

Dividend

$0.00

Beta (Volatility)

0.52 (Low)

Price

$4.30

Volume

145,721.571

Open

$4.30

Previous Close

$4.29

Daily Range

$4.23 - $4.41

52-Week Range

$2.20 - $7.95

Estimated Earnings Date

Aug 11, 2026

TLSI News

No articles available.

TLSI: Motley Fool Moneyball Superscore

64

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About TriSalus Life Sciences

TriSalus helps doctors treat hard-to-reach liver and pancreatic tumors. Its devices deliver medicine directly to tumors, improving treatment for patients. Hospitals use these systems to target cancer more precisely and efficiently.

Gadgets and Goodies: What TriSalus Sells

  • TriNav Infusion System: Delivers drugs to liver tumors through arteries; main revenue driver.
  • TriNav LV and FLX: Newer versions for larger or complex blood vessels; used in advanced liver procedures.
  • TriGuide Guiding Catheter: Supports access for TriNav LV; helps doctors reach target areas.
  • Pancreatic Infusion System: Delivers drugs to pancreatic tumors; targets difficult-to-treat cancers.

Growth Spurts and Strategic Moves

  • Launched TriNav LV and TriGuide in 2024, expanding device options for doctors.
  • Introduced TriNav FLX in June 2025 for more complex procedures.
  • Started the PROTECT registry in 2025, studying new uses for its technology.
  • Secured permanent U.S. reimbursement codes in 2025, supporting hospital adoption.
  • Partnered with MD Anderson Cancer Center for ongoing clinical studies.

Why TriSalus Gets Noticed

TriSalus focuses on U.S. hospitals, selling directly to doctors and clinics. Its technology aims to solve two main problems: getting drugs deep into tumors and overcoming the body’s resistance to treatment. The company’s devices are supported by unique reimbursement codes, making them easier for hospitals to adopt.

Five Things You Need to Know

  • Revenue was approximately $11 million in Q2 2025, up 52.3% year-on-year.
  • Gross margin was 83.9% in Q2 2025, down from 87.6% in Q2 2024.
  • Operating loss was $7.33 million in Q2 2025, improved from $8.17 million in Q2 2024.
  • All sales are U.S.-based; no international revenue reported as of June 2025.
  • Cash was $26.49 million on June 30, 2025, but future funding is needed.

Bottom Line

TriSalus has grown by expanding its device lineup and clinical research. The company remains focused on improving cancer treatment delivery, but faces ongoing financial and operational challenges.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

102

CEO

Mary T. Szela, MBA

Website

www.trisaluslifesci.com

Headquarters

Westminster, CO 80031, US

TLSI Financials

Key Financial Metrics (TTM)

Gross Margin

85.07%

Operating Margin

-62.45%

Net Income Margin

-60.85%

Return on Equity

162.57%

Return on Capital

-4645.86%

Return on Assets

-38.48%

Earnings Yield

-32.89%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$263.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

61.42M

Volume

145.72K

Avg. Volume

479.68K

Financials (TTM)

Gross Profit

$38.18M

Operating Income

-$28.03M

EBITDA

-$20.95M

Operating Cash Flow

-$19.99M

Capital Expenditure

-$305.00K

Free Cash Flow

-$20.30M

Cash & ST Invst.

$56.55M

Total Debt

$34.49M

TriSalus Life Sciences Performance Analysis

TriSalus Life Sciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 12,398,000N/A
20232023-12-31USD 18,511,00049.3%
20242024-12-31USD 29,431,00059.0%
20252025-12-31USD 45,151,00053.4%
TriSalus Life Sciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3022.3%
Q32025-09-303.1%
Q42025-12-3114.2%
Q12026-03-31-32.6%
TriSalus Life Sciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -161.55N/A
20232023-12-31USD -6.77-95.8%
20242024-12-31USD -1.31-80.6%
20252025-12-31USD -1.8440.2%
TriSalus Life Sciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3030.8%
Q32025-09-30-255.6%
Q42025-12-3178.1%
Q12026-03-31114.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$8.90M

-2.9%

Gross Profit

$7.67M

-0.0%

Gross Margin

86.18%

N/A

Market Cap

$263.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.58M

N/A

Employees

102

N/A

Net Income

$1.54M

+114.8%

EBITDA

$3.11M

+134.6%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$56.55M

+335.0%

Total Debt

$34.49M

+4.1%

Accounts Receivable

$5.22M

-4.4%

Inventory

$3.78M

-9.2%

Long Term Debt

$34.27M

+3.9%

Short Term Debt

$218.00K

+84.7%

Return on Assets

-38.48%

N/A

Return on Invested Capital

-47.35%

N/A

Free Cash Flow

-$6.62M

-26.0%

Operating Cash Flow

-$6.48M

-44.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AVRAnteris Technologies Global Corp.
$8.45+1.32%
PREPrenetics Global Limited
$18.29-3.28%
PROFProfound Medical Corp.
$6.85+1.03%
MXCTMaxCyte, Inc.
$1.24-8.15%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$6.53-0.02%
NOKNokia
$10.12-0.03%
PATHUiPath
$12.15+0.01%
JOBYJoby Aviation
$7.23-0.01%

Questions About TLSI

What is the current price of TriSalus Life Sciences?

TriSalus Life Sciences is trading at $4.29 per share.

What is the 52-week range for TriSalus Life Sciences?

Over the past 52 weeks, TriSalus Life Sciences has traded between $2.20 and $7.95.

How much debt does TriSalus Life Sciences have?

As of the most recent reporting period, TriSalus Life Sciences reported total debt of $34.49M.

How much cash does TriSalus Life Sciences have on hand?

TriSalus Life Sciences reported $56.55M in cash and cash equivalents in its most recent financial results.

What is TriSalus Life Sciences’s dividend yield?

TriSalus Life Sciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services